Phase II study of vinorelbine in patients with malignant pleural mesothelioma
Phase II study of vinorelbine in patients with malignant pleural mesothelioma
复制标题
DOI：
10.1200/jco.2000.18.23.3912
复制
发表时间：
2000-12-01
影响因子：
45.3
通讯作者：
Rudd, RM
中科院分区：
文献类型：
--
作者：
Steele, JPC;Shamash, J;Rudd, RM
目的：评价长春瑞滨30 mg/m（2）每周6周为周期的恶性胸膜间皮瘤患者的反应率和对生活质量的影响; 29例经组织学证实的恶性胸膜间皮瘤患者入选（26例男性患者和3例女性患者;中位年龄，58岁[范围，29至77岁]）。17例患者为上皮样肿瘤，2例为肉瘤样肿瘤，10例为双相肿瘤。采用国际间皮瘤兴趣组分期系统：1例患者为Ib期疾病，10例为II期疾病，8例为III期疾病，10例为IV期疾病。患者每周注射长春瑞滨30 mg/m2。一个周期包括每周六次注射。使用新指南评价实体瘤治疗反应。螺旋CT扫描测量Responses.Results：所有29例患者持有可测量的疾病，并进行评估的反应。有7例患者部分缓解（24% [95%置信区间，10%-44%]），16例患者病情稳定（55%），6例患者在治疗期间疾病进展（21%）。长春瑞滨注射的中位次数为12次（范围：2 - 30次）。生活质量的分析表明，长春瑞滨therapeutic.Conclusion：长春瑞滨的承诺，在姑息治疗恶性胸膜间皮瘤的患者，相对较低的毒性的药物表明，长春瑞滨与其他药物的组合试验应该是可行的。(C)2000年，美国临床肿瘤学会。
Purpose: To evaluate the response rate and impact on quality of life of vinorelbine given as cycles of 30 mg/m(2) weekly for 6 weeks to patients with malignant pleural mesothelioma.Patients and Methods; Twenty-nine patients with histologically proven malignant pleural mesothelioma were enrolled (26 male patients and three female patients; median age, 58 years [range, 29 to 77 years]). Seventeen patients had epithelioid tumors, two had sarcomatoid tumors, and 10 had biphasic tumors. The International Mesothelioma Interest Group staging system was used: one patient had stage Ib disease, 10 had stage II disease, eight had stage III disease, and 10 had stage IV disease. Patients were treated with weekly injections of vinorelbine 30 mg/m(2). A cycle consisted of six weekly injections. The new guidelines to evaluate the response to treatment in solid tumors were used. Responses were measured by spiral computed tomography scan.Results: All twenty-nine patients held measurable disease and were assessed for response. There were seven partial responses (24% [95% confidence interval, 10% to 44%]), 16 patients had stable disease (55%), and six patients had disease progression on therapy (21%). The median number of vinorelbine injections was 12 (range, 2 to 30). Quality-of-life analyses showed a benefit for vinorelbine therapy.Conclusion: Vinorelbine shows promise in the palliation of patients with malignant pleural mesothelioma, The relatively low toxicity of the drug suggests that trials of vinorelbine in combination with other agents should be feasible. (C) 2000 by American Society of Clinical Oncology.